ORGANIC
LETTERS
2008
Vol. 10, No. 3
509-511
Cyclopropanecarboxylic Acid Esters as
Potential Prodrugs with Enhanced
Hydrolytic Stability
David M. Bender,† Jeffrey A. Peterson,† James R. McCarthy,*,† Hakan Gunaydin,‡
Yu Takano,‡ and K. N. Houk*,‡
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana 46285, and
Department of Chemistry and Biochemistry, UniVersity of California,
Los Angeles, California 90095
mccarthy_james@lilly.com; houk@chem.ucla.edu
Received December 3, 2007
ABSTRACT
Esters of cyclopropanecarboxylic acid demonstrate a substantial increase in stability under both acid- and base-catalyzed hydrolytic conditions.
Comparison of the stability of valacyclovir 13 with the cyclopropane analogue 14 shows that at 40 C and pH 6 the half-life of 14 is >300 h
°
while the value for 13 is 69.7 h. CBS-QB3 calculations on isodesmic reactions for transfer of groups from an alkane to an ester show that a
cyclopropyl group provides hyperconjugative stabilization.
Prodrugs with ester functionalities have the significant
potential to increase the oral availability of otherwise potent
orally unavailable therapeutics.1,2 For example, the antiviral
agent valacyclovir (Valtrex) is the L-valine ester of the parent
compound acyclovir. The ester has increased the oral
bioavailability of this drug by 5-fold relative to acyclovir
via recognition and active transport by the human peptide
transporter hPepT1.3 This type of prodrug strategy has also
been employed with nucleosides, and there are currently 20
such drugs reported in the literature.4,5 One such example is
Hoe-961, which is an orally active acetate prodrug of a novel
antiviral agent for the treatment of HSV.6
We have found that cyclopropanecarboxylic acid esters
can be used as prodrugs that can provide increased stability
in the acidic environment of the stomach and the alkaline
conditions present in the intestine. Increased stability should
result in better absorption of the intact prodrug into the
plasma. The cyclopropyl group has unique conjugating
properties that make it similar to a carbon-carbon double
bond in its interaction with adjacent π-electron systems.7 This
† Eli Lilly and Co.
‡ University of California.
(1) (a) March, J. AdVanced Organic Chemistry: Reactions, Mechanisms,
and Structure, 4th ed.; John Wiley & Sons: New York, 1992; pp 378-
383. (b) Kirby, A. J. In ComprehensiVe Chemical Kinetics; Bamford, T.,
Ed.; Elsevier Publishing Co.: Amsterdam/New York, 1972; Vol. 10, pp
57-207. (c) Euranto, E. K. In The Chemistry of Carboxylic Acids and
Esters; Patai, S., Ed.; Wiley: New York, 1969; pp 505-588.
(2) (a) Testa, B.; Mayer, J. M. Hydrolysis in Drug and Prodrug
Metabolism: Chemistry, Biochemistry, and Enzymology; Wiley-VCH
GmbH: Weinheim, Germany, 2003. (b) Beaumont, K.; Webster, R.;
Gardner, L.; Dack, K. Curr. Drug Metab. 2003, 4, 461-485. (c) Ettmayer,
P.; Amidon, G. L.; Clement, B.; Teata, B. J. Med. Chem. 2004, 47, 2393-
2404.
(4) Mackman, R. L.; Cihlar, T. Ann. Rep. Med. Chem. 2004, 39, 305-
321.
(5) (a) McCarthy, J. R.; Jarvi, E. T.; Matthews, D. P.; Edwards, M. L.;
Prakash, N. J.; Bowlin, T. L.; Mehdi, S.; Bey, P. J. Am. Chem. Soc. 1989,
111, 1127-1128. (b) McCarthy, J. R.; Matthews, D. P.; Stemerick, D. M.;
Huber, E. W.; Bey, P.; Lippert, B. J.; Snyder, R. D.; Sunkara, P. S. J. Am.
Chem. Soc. 1991, 113, 7439-7440.
(6) Smee, D. F.; Morrison, A. C.; Bailey, K. W.; Sidwell, R. W. 41st
Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, Dec 16-19
2001, Abstract 1594.
(3) Weller, S.; Blum, M.; Douchette, M. Clin. Pharmacol. Ther. 1993,
54, 595-605.
10.1021/ol702892e CCC: $40.75
© 2008 American Chemical Society
Published on Web 01/09/2008